Page 5 - Pharma Sctors

Waiver for rare disease drugs brings little relief: Pharma sector

Industry bats for extending exemption to drugs that are already commercially available in India

Schedule M of Drugs and Cosmetics Act to be made must for all pharma units

Govt wants units to move towards GMP through self regulation

Delhi HC restrains Cipla from using Gluco-C or Gluco-D trademarks

Zydus argued that Cipla started branding its Glucose product under Gluco C ++ and Gluco D ++, in order to create confusion in the minds of customers

'4IR': The booster pharma majors are taking to improve productivity

Large manufacturers are leveraging new-age technologies and advanced analytics to improve productivity and reduce deviations in production processes

Divis Lab, Sun Pharma: Current breakout may lead Pharma index to new peak

Pharm index has broken out on upside, with the positive rally anticipated to hit 14,450

Lupin likely to demerge its active pharmaceutical ingredients business

As such the API business contributes around 7 percent to Lupin's overall turnover

Self-regulatory body for pharma industry on cards: Mansukh Mandaviya

Mandaviya says joint squads of state and Centre formed for risk-based assessment of plants

Fewer Indian pharma plants get US FDA action notice in 2023, so far

6 per cent of inspections in first 6 months of CY23 resulted in OAI status

Lupin signs MoU with Maharashtra govt to combat rising prevalence of CVD

Collaboration to enhance healthcare services, ensure timely diagnosis, and improve accessibility of healthcare services

Regulatory woes torpedo PE/VC deals in e-pharma sector, shows data

Focus on profitability, and less options other reasons behind the slowdown seen till May this year

USFDA inspections of Indian sites still below pre-Covid-19 levels

On an average Indian sites have had only a 9% share of total global inspections, analysts point out

India's contribution to global clinical trials at 4% during 2010-22: Study

Trials sponsored by top 20 pharma companies increased 10% since 2013

Online pharmacies suffer without regulatory prescriptions in India

The absence of a legal framework governing this fast-growing segment of the pharma retailing business is causing confusion in the industry

Indian pharma R&D spends stay stagnant three years after pandemic downturn

Spends are now lower relative to sales than before Covid-19, stand at 4.4% of net sales, compared with 20% in the US

Pharma, healthcare Q3FY23 preview: Cost pressures abating to aid margins

Hospitals are expected to report a soft Q3 result due to a mix of seasonality and easing pent-up demand, however, average revenue per occupied bed is likely to remain steady

Pharma firms with India focus preferred as US market concerns grow

Steady outlook and higher returns triggers for companies refining their strategy

BDR Pharma prostate cancer drug at 1/3rd of innovator brand price

The price for a bottle of 60 tablets is Rs 22,500 and for a bottle of 120 tablets is Rs 45,000

Drug regulator halts production at Maiden Pharma's Sonipat unit

Centre forms panel to analyse causal relation between deaths and cough syrups

Cash is king! Investing strategies to ride out choppy markets

They turn cautious and prefer defensive bets

Top headlines: Growth forecast, Maiden Pharma cough syrup issue, and more

From World Bank slashing India's economic growth to Maiden Pharma's cough syrup issue, here are the top headlines on Friday morning